Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer
Standard
Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer. / Mathey, Sabrina; Graeser, Monika Karla; Zu Eulenburg, Christine; Woelber, Linn; Trillsch, Fabian; Jänicke, Fritz; Müller, Volkmar; Milde-Langosch, Karin; Mahner, Sven.
In: ONCOLOGY-BASEL, Vol. 85, No. 2, 01.01.2013, p. 69-77.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer
AU - Mathey, Sabrina
AU - Graeser, Monika Karla
AU - Zu Eulenburg, Christine
AU - Woelber, Linn
AU - Trillsch, Fabian
AU - Jänicke, Fritz
AU - Müller, Volkmar
AU - Milde-Langosch, Karin
AU - Mahner, Sven
N1 - Copyright © 2013 S. Karger AG, Basel.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - OBJECTIVES: Angiogenesis plays an important role in ovarian cancer. The interaction of platelet-derived growth factor receptor-beta (PDGFR-β) with vascular endothelial growth factor (VEGF) in the process of angiogenesis may represent an essential feature in the progression of the disease.METHODS: Patients with epithelial ovarian cancer, who underwent primary surgery and platinum-based first-line chemotherapy, were included. A total of 133 serum samples from 39 patients were analyzed. Samples were prospectively collected at 4 time points: (1) before surgery, (2) after surgery and before chemotherapy, (3) during chemotherapy and (4) after chemotherapy. Serum PDGFR-β was quantified by ELISA. We analyzed the correlation of serum levels to chemotherapy response, progression-free and overall survival (PFS and OS) and the serum markers CA-125 and VEGF-165.RESULTS: Serum concentration of PDGFR-β ranged between 4 and 72 ng/ml and increased significantly during first-line chemotherapy (p = 0.019). PDGFR-β serum concentrations showed an inverse correlation with CA-125 and VEGF-165 after chemotherapy (r = -0.495, p = 0.003 and r = -0.345, p = 0.04, respectively). Increased PDGFR-β serum levels after chemotherapy were significantly correlated with better PFS (p = 0.026) and OS (p = 0.013) in a univariate analysis.CONCLUSION: PDGFR-β might be a useful biomarker in terms of prognosis and could be important as antiangiogenic agents become a component of standard treatment in ovarian cancer.
AB - OBJECTIVES: Angiogenesis plays an important role in ovarian cancer. The interaction of platelet-derived growth factor receptor-beta (PDGFR-β) with vascular endothelial growth factor (VEGF) in the process of angiogenesis may represent an essential feature in the progression of the disease.METHODS: Patients with epithelial ovarian cancer, who underwent primary surgery and platinum-based first-line chemotherapy, were included. A total of 133 serum samples from 39 patients were analyzed. Samples were prospectively collected at 4 time points: (1) before surgery, (2) after surgery and before chemotherapy, (3) during chemotherapy and (4) after chemotherapy. Serum PDGFR-β was quantified by ELISA. We analyzed the correlation of serum levels to chemotherapy response, progression-free and overall survival (PFS and OS) and the serum markers CA-125 and VEGF-165.RESULTS: Serum concentration of PDGFR-β ranged between 4 and 72 ng/ml and increased significantly during first-line chemotherapy (p = 0.019). PDGFR-β serum concentrations showed an inverse correlation with CA-125 and VEGF-165 after chemotherapy (r = -0.495, p = 0.003 and r = -0.345, p = 0.04, respectively). Increased PDGFR-β serum levels after chemotherapy were significantly correlated with better PFS (p = 0.026) and OS (p = 0.013) in a univariate analysis.CONCLUSION: PDGFR-β might be a useful biomarker in terms of prognosis and could be important as antiangiogenic agents become a component of standard treatment in ovarian cancer.
KW - Adult
KW - Aged
KW - Antineoplastic Combined Chemotherapy Protocols
KW - CA-125 Antigen
KW - Carboplatin
KW - Disease-Free Survival
KW - Female
KW - Humans
KW - Induction Chemotherapy
KW - Kaplan-Meier Estimate
KW - Middle Aged
KW - Neoplasms, Glandular and Epithelial
KW - Ovarian Neoplasms
KW - Paclitaxel
KW - Receptor, Platelet-Derived Growth Factor beta
KW - Treatment Outcome
KW - Tumor Markers, Biological
KW - Vascular Endothelial Growth Factor A
U2 - 10.1159/000351032
DO - 10.1159/000351032
M3 - SCORING: Journal article
C2 - 23860180
VL - 85
SP - 69
EP - 77
JO - ONCOLOGY-BASEL
JF - ONCOLOGY-BASEL
SN - 0030-2414
IS - 2
ER -
